



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Letter to the Editor

Real-world evidence in antiretroviral therapy: drug safety data



Dear Editor:

Adverse drug reactions (ADR), despite being underreported, are a serious public health problem, associating with high mortality and morbidity.^{1,2} In the case of antiretroviral therapy (ART), some studies have demonstrated that ADR is the main factor for drug change, often preventing adherence by the patient to treatment and reducing the durability of the initial regimen.^{3,4}

A recent case-control study nested in a cohort of people living with HIV/AIDS was published in your journal to investigate factors associated with the modification of first-line ART due to ADR.⁵ This study is important because ART in Brazil is recommended for all people living with HIV, regardless of their CD4 count. In addition, the methodology of the study allowed researchers to circumvent limitations of other methods such as spontaneous notifications.

In Portugal, the recommendations for this type of therapy are similar to those in Brazil. We conducted a retrospective observational study in a consecutive sample of people living with HIV/AIDS who started ART between 2007 and 2011, and who were followed in a tertiary public hospital of Northern Portugal. In that study, we sought to identify the main reasons for changing ART through the information contained in hospital prescriptions and by examining whether detected adverse reactions had been reported to the Portuguese Pharmacovigilance System. From the 517 patients, 259 changed ART, of which 60 (24%) were due to ADR. However, only 6 (8.5%) of the changes of ART due to ADR had been reported to the Portuguese Pharmacovigilance System. The most commonly involved System Organ Class (SOC) was “Skin and subcutaneous tissue disorder”.

Therefore, we found a similar frequency of ADR-associated ART changes in Portugal compared to that described by Azevedo et al. Our results highlight that despite ADR being a common reason for therapeutic change in people living with HIV/AIDS, they tend to be underreported. We would like to emphasize the importance of reporting ADR to the Pharmacovigilance System, because it is the only way to get real world drug safety data and to increase knowledge about the marketed drugs.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

This letter was supported by National Funds through FCT - Fundação para a Ciência e a Tecnologia, I.P., within CINTESIS, R&D Unit (reference UIDB/4255/2020).”.

REFERENCES

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *J Am Med Assoc.* 1998, <http://dx.doi.org/10.1001/jama.279.15.1200>.
2. European Commission, Memo/08/782 Strengthening pharmacovigilance to reduce adverse effects of medicines; 2008.
3. Prosperi MCF, Fabbiani M, Fanti I, et al. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. *BMC Infect Dis.* 2012, <http://dx.doi.org/10.1186/1471-2334-12-296>.
4. Torres TS, Cardoso SW, Velasque LS, Veloso VG, Grinsztejn B. Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age. *Brazilian J Infect Dis.* 2014, <http://dx.doi.org/10.1016/j.bjid.2013.04.005>.
5. Azevedo LN, Ximenes RAA, Monteiro P, Montarroyos UR, Miranda-Filho DB. Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV/AIDS. *Brazilian J Infect Dis.* 2020;24:65–72, <http://dx.doi.org/10.1016/j.bjid.2019.11.002>.

Ana-Marta Silva ^{a,b,c,*},
Marta Pereira ^d, Cláudia Camila Dias ^{b,c}, Ângela Ventura ^d,
Bernardo Sousa-Pinto ^{b,c}

^a University of Porto, Faculty of Medicine, Northern Pharmacovigilance Centre (UFPorto), Porto, Portugal

^b University of Porto, Faculty of Medicine, Health Information and Decision (MEDCIDS), Porto, Portugal

^c University of Porto, Faculty of Medicine, Center for Health Technology and Service Research (CINTESIS), Porto, Portugal

^d Pharmacy of Centro Hospitalar Universitário do Porto (CHUP), Porto, Portugal

Corresponding author.

E-mail address: ammsilva@med.up.pt (A. Silva).

Accepted 26 April 2020

Available online 15 May 2020

<https://doi.org/10.1016/j.bjid.2020.04.013>

© 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).